Lilly presented data from multiple clinical programs as part of October's annual meeting of the European Association for the Study of Diabetes, including Phase 2 data for a combination of amylin agonist eloralintide and Lilly's blockbuster cardiometabolic drug tirzepatide (Mounjaro/Zepbound).
Lilly's strong leadership in weight-loss drugs should drive industry-leading growth, given its approved drugs and well-positioned next-generation weight-loss drugs in the pipeline.
The risks to success for Kisunla remain high because of bottlenecks in patient diagnosis, required scans and monitoring, and competition, particularly from Eisai/Biogen (Leqembi) and Roche (pipeline drug trontinemab).
|
Metric
|
LLY
|
NVO
|
MRK
|
|---|---|---|---|
Price/Earnings (Normalized) | 36.51 | 8.30 | 44.80 |
Price/Book Value | 30.26 | 4.90 | 8.47 |
Price/Sales | 12.94 | 3.23 | 5.36 |
Price/Cash Flow | 31.35 | 7.74 | 16.10 |
|
Metric
|
LLY
|
NVO
|
MRK
|
|---|---|---|---|
Quick Ratio | 0.68 | 0.64 | 0.71 |
Current Ratio | 1.35 | 0.87 | 1.32 |
Interest Coverage | — | — | 4.28 |
|
Metric
|
LLY
|
NVO
|
MRK
|
|---|---|---|---|
Return on Assets (Normalized) | 24.05% | 21.31% | 6.27% |
Return on Equity (Normalized) | 105.62% | 59.99% | 16.68% |
Return on Invested Capital (Normalized) | 39.55% | 34.79% | 9.82% |
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Johnson & Johnson
JNJ
| LOCK|L#<Sr$ | LOCK|%@ | $623B | |||
| AbbVie Inc
ABBV
| LOCK|TYH<%T^ | LOCK|@P | $459B | |||
| Merck & Co Inc
MRK
| LOCK|R##!$@ | LOCK|^K% | $355B | |||
| Roche Holding AG ADR
RHHBY
| LOCK|@H<!H$? | LOCK|^l | $334B | |||
| Novartis AG ADR
NVS
| LOCK|Rpht%Y>V | LOCK|BL | $268B | |||
| AstraZeneca PLC
AZN
| LOCK|?Z@%v&^$ | LOCK|&zN | $248B | |||
| Amgen Inc
AMGN
| LOCK|$hN<^Jlb | LOCK|WG< | $220B | |||
| Gilead Sciences Inc
GILD
| LOCK|&j#$^^X | LOCK|^Y# | $183B | |||
| Novo Nordisk AS ADR
NVO
| LOCK|sbf!qZj | LOCK|<@ | $167B |
United States